In addition, based on the fact that novel anti-HER2 drugs like T-DXd are being used against HER2-low breast tumors and are being successful [105,319,320,321], in the near future CAR-T cells against TNBC patients may be tested in HER2-low subjects. The gene discussed is ERBB2; the disease is breast neoplasm.